GlassScriptPhysician profile
Yun Qian
NPI 1861940975
$2,592.09
in general payments reported to CMS, 2019-2025
28 companies · $578 in 2025
The $578 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $223 · 2023: $340 · 2024: $1,106 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.38 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.89 | 2021-2025 | Tezspire, Fasenra |
| Janssen Biotech, INC. | $268.82 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $191.53 | 2021-2025 | Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $176.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $172.45 | 2022-2024 | Reblozyl, Opdualag |
| Celgene Corporation | $148.56 | 2024-2025 | Reblozyl |
| Emd Serono, INC. | $141.84 | 2021-2024 | |
| Argenx US, INC. | $110.62 | 2025 | Vyvgart |
| Gilead Sciences, INC. | $102.90 | 2023 | Trodelvy |
| Merck Sharp & Dohme LLC | $96.19 | 2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $89.99 | 2024 | |
| Daiichi Sankyo INC. | $71.53 | 2024-2025 | Injectafer |
| Coherus Oncology, INC. | $65.79 | 2021-2025 | Loqtorzi, Udenyca |
| Amgen INC. | $60.99 | 2022 | |
| Genzyme Corporation | $59.74 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.33 | 2024-2025 | Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $49.29 | 2022-2024 | Ultomiris |
| Janssen Scientific Affairs, LLC | $42.86 | 2024 | Rybrevant |
| Puma Biotechnology, INC. | $40.48 | 2023 | Nerlynx |
| Pharmacosmos Therapeutics INC. | $35.91 | 2023-2024 | Cosela, Monoferric |
| Karyopharm Therapeutics INC. | $33.38 | 2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $32.21 | 2024 | Vpriv |
| Agios Pharmaceuticals, INC. | $32.19 | 2024 | |
| Organon LLC | $24.58 | 2022 | |
| Mirati Therapeutics, INC. | $23.12 | 2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $22.13 | 2023 | Qinlock |
| Genentech USA, INC. | $21.95 | 2024 | Phesgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun Qian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.